Referencias 1

Cosgrove, S. B., Cleaver, D. M., King, V.L., Gilmer, A. R., Daniels, A. E., Wren, J. A. & Stegemann, M. R. (2015). Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Veterinary Dermatology, 26(3), 171-179.

Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Walsh, K. F., Follis, S. I., King, V. I., Tena, J-K. S. & Stegemann, M. R. (2013). A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client‐owned dogs with atopic dermatitis. Veterinary Dermatology, 24(6), 587-e142.

Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Martin, D. D., Walsh, K. F., Harfst, J. A., Follis, S. L., King, V. L., Boucher, J. F. & Stegemann, M. R. (2013). Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Veterinary Dermatology, 24(5), 479–e114.

Favrot, C., Steffan, J., Seewald, W. & Picco, F. (2010) A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Veterinary Dermatology, 21(1), 23-31.

Gadeyne, C., Little, P., King, V. L., Edwards, N., Davis, K., & Stegemann, M. R. (2014). Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Veterinary Dermatology, 25(6), 512–e86.

Little, P. R., King, V. L., Davis, K. R., Cosgrove, S. B. & Stegemann, M. R. (2015). A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Veterinary Dermatology, 26(1), 23-30.

Moyaert, H., Van Brussel, L., Borowski, S., Escalada, M., Mahabir, S. P., Walters, R. R. & Stegemann, M. R. (2017). A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Veterinary Dermatology, 28(6), 593-e145.

Nuttall, T. J., McEwan, N. A., Bensignor, E., Cornegliani, L., Löwenstein, C. & Rème, C. A. (2012). Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis. Veterinary Dermatology, 23(1), 4-10.

Picco, F., Zini, E., Nett, C., Naegeli, C., Bigler, B., Rüfenacht, S., Roosje, P., Gutzwiller, M. E. R., Wilhelm, S., Pfister, J., Meng, E. & Favrot C. (2008). A prospective study on canine atopic dermatitis and food-induced allergic dermatitis in Switzerland. Veterinary Dermatology, 19(3), 150-155.

Souza, C. P., Schissler, J. R., Rosychuk, R. A. W. & Simpson, A. C. (2018). A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Veterinary Dermatology, 29(6), 489–e164.

Thelen, A., Mueller, R. S., Linek, M., Peters, S., Stechmann, K. & Steffan, J. (2006) Influence of food intake on the clinical response to cyclosporin A in canine atopic dermatitis. Veterinary Record, 159, 854-856.

Vincent, A. L., Lam, A. T. H., Marcucci, C. S., Zewe, C. M., Falk, E. F. & Ferrer, L. (2017). A retrospective study to assess antipruritic efficacy of lokivetmab in dogs with canine atopic dermatitis. En: Abstracts of the North American Veterinary Dermatology Forum 26–29 April 2017 Orlando. Veterinary Dermatology, 28(5), 426-455.